Shanghai Pharmaceuticals (SHA:601607) subsidiary Changzhou Pharmaceutical Factory received a drug registration certificate from China's National Medical Products Administration for its rosuvastatin ezetimibe tablets, according to a Friday filing with the Shanghai Stock Exchange.
The drug is indicated for high cholesterol or homozygous familial hypercholesterolemia, the company said.
Mainland Chinese hospitals have so far purchased 25.7 million yuan worth of the drug in 2025.
ASE Technology's (TPE:3711) attributable profit surged to NT$21.1 billion in the second quarter from NT$7.52 billion a year earlier.Diluted earnings per share rose to NT$4.61 from NT$1.70 a year earlier.Revenue climbed 27% year over year to NT$191.1 billion due to higher semiconductor assembly, testing and electronic manufacturing services sales. On a sequential basis, revenue increased 10%.Gross margin improved to 21% from 20% in the first quarter, while operating margin rose to 11% from 10%, it said.
Fitch Ratings affirmed Sinochem International's (SHA:600500) long-term foreign-currency issuer default rating and senior unsecured rating at A-, with a stable outlook, the ratings firm said Thursday.The new ratings reflected the state-owned firm's parent, Sinochem Holdings Corporation, which was rated with "Low" legal, "Medium" strategic, and "High" operational incentives to support Sinochem.The ratings firm decided to withdraw the ratings due to commercial reasons.
Cinda Securities (SHA:601059) posted first-half attributable net profit of 1.10 billion yuan, up 7.2% from 1.02 billion yuan the previous year.Earnings per share were unchanged at 0.30 yuan, according to a filing with the Shanghai bourseOperating revenue climbed 20% year over year to 2.44 billion yuan from 2.04 billion yuan.Shares of the brokerage were down 1% in recent trade.